We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
Cap. Flow
-$1.47B
Cap. Flow %
-27.24%
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34

Top Buys

Rank Stock Value
1
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
+$78.1M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$77.1M
3
CVS icon
CVS Health
CVS
+$59.3M
4
CELG
Celgene Corp
CELG
+$58.5M
5
GH icon
Guardant Health
GH
+$56.5M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$149M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$98.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$81.7M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81M
5
EW icon
Edwards Lifesciences
EW
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDHL
126
Redhill Biopharma
RDHL
$4.26M
$303K 0.01%
55
-230
-81% -$1.76M
ALIM
127
DELISTED
Alimera Sciences
ALIM
$180K ﹤0.01%
16,667
– –
WMGIZ
128
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$109K ﹤0.01%
8,746,583
– –
XYLO
129
DELISTED
Xylo Technologies
XYLO
$39K ﹤0.01%
375
– –
ALKS icon
130
Alkermes
ALKS
$8.09B
– –
-145,000
Closed -$6.15M
ANAB icon
131
PUT
AnaptysBio
ANAB
$1.52B
– –
-20,000
Closed -$2M
CHRS icon
132
Coherus Oncology
CHRS
$217M
– –
-1,722,400
Closed -$28.4M
CPRX
133
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,102,000
Closed -$4.17M
CRSP icon
134
CRISPR Therapeutics
CRSP
$4.63B
– –
-496,200
Closed -$22M
DBVT
135
DBV Technologies
DBVT
$805M
– –
-66,520
Closed -$14.9M
LKFT
136
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-391,631
Closed -$44M
INSM icon
137
Insmed
INSM
$22.5B
– –
-1,829,300
Closed -$37M
IRWD icon
138
CALL
Ironwood Pharmaceuticals
IRWD
$596M
– –
-179,100
Closed -$2.77M
JAZZ icon
139
Jazz Pharmaceuticals
JAZZ
$16.1B
– –
-884,000
Closed -$149M
JNJ icon
140
Johnson & Johnson
JNJ
$645B
– –
-414,100
Closed -$57.2M
LAB icon
141
Standard BioTools
LAB
$326M
– –
-1,077,801
Closed -$8.07M
MCK icon
142
CALL
McKesson
MCK
$106B
– –
-50,000
Closed -$6.63M
MCK icon
143
McKesson
MCK
$106B
– –
-74,100
Closed -$9.83M
MD icon
144
Pediatrix Medical
MD
$2.17B
– –
-1,469,300
Closed -$68.6M
RCKT icon
145
Rocket Pharmaceuticals
RCKT
$333M
– –
-775,000
Closed -$19.1M
SEM
146
DELISTED
Select Medical
SEM
– –
-1,920,424
Closed -$19M
STIM icon
147
Neuronetics
STIM
$132M
– –
-150,000
Closed -$4.81M
TFX icon
148
Teleflex
TFX
$5.93B
– –
-157,300
Closed -$41.9M
VRTX icon
149
CALL
Vertex Pharmaceuticals
VRTX
$124B
– –
-100,000
Closed -$19.3M
VYNE icon
150
VYNE Therapeutics
VYNE
– –
-131
Closed -$4.66M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2018 Portfolio in Review

As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.

  • OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
  • OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
  • OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
  • OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
  • OrbiMed opened 19 new positions and closed 34 in Q4 2018.
  • OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.